Threshold Pharmaceuticals $THLD got hammered on Thursday after the company announced interim results from its tarloxotinib program which failed to meet its target. The company now plans to discontinue with the study and focus on early-stage candidates. Even though the trial achieved the primary interim response rate endpoint in patients with recurrent or metastatic squamous cell carcinoma of the skin, it failed to achieve in patients with metastatic squamous cell carcinoma of the head and neck, or with advanced EGFR-mutant, T790M-negative non-small cell lung cancer.